Washington Nursing Dialysis is a medicare approved dialysis facility center in Washington, District Of Columbia and it has 9 dialysis stations. It is located in District Of Columbia county at 2425 25th Street Se, Washington, DC, 20020. You can reach out to the office of Washington Nursing Dialysis at (202) 678-0036. This dialysis clinic is managed and/or owned by Davita. Washington Nursing Dialysis has the following ownership type - Profit. It was first certified by medicare in November, 2009. The medicare id for this facility is 092524 and it accepts patients under medicare ESRD program.
| Name | Washington Nursing Dialysis |
|---|---|
| Location | 2425 25th Street Se, Washington, District Of Columbia |
| No. of Dialysis Stations | 9 |
| Medicare ID | 092524 |
| Managed By | Davita |
| Ownership Type | Profit |
| Late Shifts | No |
| 2425 25th Street Se, Washington, District Of Columbia, 20020 | |
| (202) 678-0036 | |
News Archive
Learning the secrets of how pathogenic bacteria manage to survive in the body of an animal or human may carry great implications for future development of new and better medical treatments. Now, scientists at the University of Maryland School of Dentistry have unraveled one important secret of bacterial adaptation.
Organogenesis, Inc. announced today that it has filed a Premarket Approval Application (PMA) with the U.S. Food and Drug Administration (FDA) for its CelTx(TM), a living cellular construct for oral soft tissue regeneration. If approved, CelTx will be the first, living cell-based technology that is FDA-approved for use in the dental market.
Many cultures hold that stress during pregnancy affects a woman's unborn child. However, there has been surprisingly little research on the topic.
Lumos Pharma, Inc., a clinical stage biopharmaceutical company focused on development and commercialization of therapeutics for rare and neglected diseases, today announced that it has acquired the license for LUM-201, an investigational orally administered small molecule that promotes secretion of growth hormone from the pituitary gland, from Ammonett Pharma LLC.
› Verified 9 days ago
| NPI Number | 1033357348 |
| Organization Name | Washington Nursing Facility |
| Doing Business As | Total Renal Care Inc |
| Address | 2425 25th St Se Washington, District Of Columbia, 20020 |
| Phone Number | (202) 678-0013 |
News Archive
Learning the secrets of how pathogenic bacteria manage to survive in the body of an animal or human may carry great implications for future development of new and better medical treatments. Now, scientists at the University of Maryland School of Dentistry have unraveled one important secret of bacterial adaptation.
Organogenesis, Inc. announced today that it has filed a Premarket Approval Application (PMA) with the U.S. Food and Drug Administration (FDA) for its CelTx(TM), a living cellular construct for oral soft tissue regeneration. If approved, CelTx will be the first, living cell-based technology that is FDA-approved for use in the dental market.
Many cultures hold that stress during pregnancy affects a woman's unborn child. However, there has been surprisingly little research on the topic.
Lumos Pharma, Inc., a clinical stage biopharmaceutical company focused on development and commercialization of therapeutics for rare and neglected diseases, today announced that it has acquired the license for LUM-201, an investigational orally administered small molecule that promotes secretion of growth hormone from the pituitary gland, from Ammonett Pharma LLC.
› Verified 9 days ago
| NPI Number | 1427441948 |
| Organization Name | Georgetown National Home Training |
| Doing Business As | Leaton Dialysis Llc |
| Address | 1225 S Capitol St Sw Washington, District Of Columbia, 20003 |
| Phone Number | (615) 341-5875 |
News Archive
Learning the secrets of how pathogenic bacteria manage to survive in the body of an animal or human may carry great implications for future development of new and better medical treatments. Now, scientists at the University of Maryland School of Dentistry have unraveled one important secret of bacterial adaptation.
Organogenesis, Inc. announced today that it has filed a Premarket Approval Application (PMA) with the U.S. Food and Drug Administration (FDA) for its CelTx(TM), a living cellular construct for oral soft tissue regeneration. If approved, CelTx will be the first, living cell-based technology that is FDA-approved for use in the dental market.
Many cultures hold that stress during pregnancy affects a woman's unborn child. However, there has been surprisingly little research on the topic.
Lumos Pharma, Inc., a clinical stage biopharmaceutical company focused on development and commercialization of therapeutics for rare and neglected diseases, today announced that it has acquired the license for LUM-201, an investigational orally administered small molecule that promotes secretion of growth hormone from the pituitary gland, from Ammonett Pharma LLC.
› Verified 9 days ago
| NPI Number | 1871032102 |
| Organization Name | Washington Center For Aging |
| Doing Business As | Total Renal Care, Inc. |
| Address | 2601 18th St Ne Washington, District Of Columbia, 20018 |
| Phone Number | (202) 269-1563 |
News Archive
Learning the secrets of how pathogenic bacteria manage to survive in the body of an animal or human may carry great implications for future development of new and better medical treatments. Now, scientists at the University of Maryland School of Dentistry have unraveled one important secret of bacterial adaptation.
Organogenesis, Inc. announced today that it has filed a Premarket Approval Application (PMA) with the U.S. Food and Drug Administration (FDA) for its CelTx(TM), a living cellular construct for oral soft tissue regeneration. If approved, CelTx will be the first, living cell-based technology that is FDA-approved for use in the dental market.
Many cultures hold that stress during pregnancy affects a woman's unborn child. However, there has been surprisingly little research on the topic.
Lumos Pharma, Inc., a clinical stage biopharmaceutical company focused on development and commercialization of therapeutics for rare and neglected diseases, today announced that it has acquired the license for LUM-201, an investigational orally administered small molecule that promotes secretion of growth hormone from the pituitary gland, from Ammonett Pharma LLC.
› Verified 9 days ago
| NPI Number | 1467950634 |
| Organization Name | La Plata Dialysis |
| Doing Business As | Dalhart Dialysis Llc |
| Address | 6700 Crain Hwy La Plata, Maryland, 20646 |
| Phone Number | (615) 341-5875 |
News Archive
Learning the secrets of how pathogenic bacteria manage to survive in the body of an animal or human may carry great implications for future development of new and better medical treatments. Now, scientists at the University of Maryland School of Dentistry have unraveled one important secret of bacterial adaptation.
Organogenesis, Inc. announced today that it has filed a Premarket Approval Application (PMA) with the U.S. Food and Drug Administration (FDA) for its CelTx(TM), a living cellular construct for oral soft tissue regeneration. If approved, CelTx will be the first, living cell-based technology that is FDA-approved for use in the dental market.
Many cultures hold that stress during pregnancy affects a woman's unborn child. However, there has been surprisingly little research on the topic.
Lumos Pharma, Inc., a clinical stage biopharmaceutical company focused on development and commercialization of therapeutics for rare and neglected diseases, today announced that it has acquired the license for LUM-201, an investigational orally administered small molecule that promotes secretion of growth hormone from the pituitary gland, from Ammonett Pharma LLC.
› Verified 9 days ago
| NPI Number | 1487156253 |
| Organization Name | Catawba County |
| Doing Business As | Total Renal Care Of North Carolina Llc |
| Address | 1900 3rd Ave Lane Se Hickory, North Carolina, 28602 |
| Phone Number | (615) 341-5875 |
News Archive
Learning the secrets of how pathogenic bacteria manage to survive in the body of an animal or human may carry great implications for future development of new and better medical treatments. Now, scientists at the University of Maryland School of Dentistry have unraveled one important secret of bacterial adaptation.
Organogenesis, Inc. announced today that it has filed a Premarket Approval Application (PMA) with the U.S. Food and Drug Administration (FDA) for its CelTx(TM), a living cellular construct for oral soft tissue regeneration. If approved, CelTx will be the first, living cell-based technology that is FDA-approved for use in the dental market.
Many cultures hold that stress during pregnancy affects a woman's unborn child. However, there has been surprisingly little research on the topic.
Lumos Pharma, Inc., a clinical stage biopharmaceutical company focused on development and commercialization of therapeutics for rare and neglected diseases, today announced that it has acquired the license for LUM-201, an investigational orally administered small molecule that promotes secretion of growth hormone from the pituitary gland, from Ammonett Pharma LLC.
› Verified 9 days ago
| NPI Number | 1821591967 |
| Organization Name | Mebane Dialysis |
| Doing Business As | Renal Treatment Centers - Mid-atlantic, Inc. |
| Address | 616 N First St Mebane, North Carolina, 27302 |
| Phone Number | (615) 341-5875 |
News Archive
Learning the secrets of how pathogenic bacteria manage to survive in the body of an animal or human may carry great implications for future development of new and better medical treatments. Now, scientists at the University of Maryland School of Dentistry have unraveled one important secret of bacterial adaptation.
Organogenesis, Inc. announced today that it has filed a Premarket Approval Application (PMA) with the U.S. Food and Drug Administration (FDA) for its CelTx(TM), a living cellular construct for oral soft tissue regeneration. If approved, CelTx will be the first, living cell-based technology that is FDA-approved for use in the dental market.
Many cultures hold that stress during pregnancy affects a woman's unborn child. However, there has been surprisingly little research on the topic.
Lumos Pharma, Inc., a clinical stage biopharmaceutical company focused on development and commercialization of therapeutics for rare and neglected diseases, today announced that it has acquired the license for LUM-201, an investigational orally administered small molecule that promotes secretion of growth hormone from the pituitary gland, from Ammonett Pharma LLC.
› Verified 9 days ago
| NPI Number | 1306338306 |
| Organization Name | Roanoke-chowan Dialysis |
| Doing Business As | Renal Treatment Centers Mid Atlantic Inc |
| Address | 626 W Main St Murfreesboro, North Carolina, 27855 |
| Phone Number | (615) 341-5875 |
News Archive
Learning the secrets of how pathogenic bacteria manage to survive in the body of an animal or human may carry great implications for future development of new and better medical treatments. Now, scientists at the University of Maryland School of Dentistry have unraveled one important secret of bacterial adaptation.
Organogenesis, Inc. announced today that it has filed a Premarket Approval Application (PMA) with the U.S. Food and Drug Administration (FDA) for its CelTx(TM), a living cellular construct for oral soft tissue regeneration. If approved, CelTx will be the first, living cell-based technology that is FDA-approved for use in the dental market.
Many cultures hold that stress during pregnancy affects a woman's unborn child. However, there has been surprisingly little research on the topic.
Lumos Pharma, Inc., a clinical stage biopharmaceutical company focused on development and commercialization of therapeutics for rare and neglected diseases, today announced that it has acquired the license for LUM-201, an investigational orally administered small molecule that promotes secretion of growth hormone from the pituitary gland, from Ammonett Pharma LLC.
› Verified 9 days ago
| NPI Number | 1215459953 |
| Organization Name | Annandale Dialysis |
| Doing Business As | Neoporte Dialysis Llc |
| Address | 7060 Columbia Pike Annandale, Virginia, 22003 |
| Phone Number | (615) 341-5875 |
News Archive
Learning the secrets of how pathogenic bacteria manage to survive in the body of an animal or human may carry great implications for future development of new and better medical treatments. Now, scientists at the University of Maryland School of Dentistry have unraveled one important secret of bacterial adaptation.
Organogenesis, Inc. announced today that it has filed a Premarket Approval Application (PMA) with the U.S. Food and Drug Administration (FDA) for its CelTx(TM), a living cellular construct for oral soft tissue regeneration. If approved, CelTx will be the first, living cell-based technology that is FDA-approved for use in the dental market.
Many cultures hold that stress during pregnancy affects a woman's unborn child. However, there has been surprisingly little research on the topic.
Lumos Pharma, Inc., a clinical stage biopharmaceutical company focused on development and commercialization of therapeutics for rare and neglected diseases, today announced that it has acquired the license for LUM-201, an investigational orally administered small molecule that promotes secretion of growth hormone from the pituitary gland, from Ammonett Pharma LLC.
› Verified 9 days ago
| NPI Number | 1548798341 |
| Organization Name | Stone Ridge Dialysis |
| Doing Business As | Amity Dialysis Llc |
| Address | 24640 Southpoint Dr Ste 160 Chantilly, Virginia, 20152 |
| Phone Number | (615) 341-5875 |
News Archive
Learning the secrets of how pathogenic bacteria manage to survive in the body of an animal or human may carry great implications for future development of new and better medical treatments. Now, scientists at the University of Maryland School of Dentistry have unraveled one important secret of bacterial adaptation.
Organogenesis, Inc. announced today that it has filed a Premarket Approval Application (PMA) with the U.S. Food and Drug Administration (FDA) for its CelTx(TM), a living cellular construct for oral soft tissue regeneration. If approved, CelTx will be the first, living cell-based technology that is FDA-approved for use in the dental market.
Many cultures hold that stress during pregnancy affects a woman's unborn child. However, there has been surprisingly little research on the topic.
Lumos Pharma, Inc., a clinical stage biopharmaceutical company focused on development and commercialization of therapeutics for rare and neglected diseases, today announced that it has acquired the license for LUM-201, an investigational orally administered small molecule that promotes secretion of growth hormone from the pituitary gland, from Ammonett Pharma LLC.
› Verified 9 days ago
| NPI Number | 1790213593 |
| Organization Name | Chantilly Dialysis |
| Doing Business As | Ogano Dialysis Llc |
| Address | 14225 Sullyfield Cir Ste A Chantilly, Virginia, 20151 |
| Phone Number | (615) 341-5875 |
News Archive
Learning the secrets of how pathogenic bacteria manage to survive in the body of an animal or human may carry great implications for future development of new and better medical treatments. Now, scientists at the University of Maryland School of Dentistry have unraveled one important secret of bacterial adaptation.
Organogenesis, Inc. announced today that it has filed a Premarket Approval Application (PMA) with the U.S. Food and Drug Administration (FDA) for its CelTx(TM), a living cellular construct for oral soft tissue regeneration. If approved, CelTx will be the first, living cell-based technology that is FDA-approved for use in the dental market.
Many cultures hold that stress during pregnancy affects a woman's unborn child. However, there has been surprisingly little research on the topic.
Lumos Pharma, Inc., a clinical stage biopharmaceutical company focused on development and commercialization of therapeutics for rare and neglected diseases, today announced that it has acquired the license for LUM-201, an investigational orally administered small molecule that promotes secretion of growth hormone from the pituitary gland, from Ammonett Pharma LLC.
› Verified 9 days ago
| Dialysis patients with Hemoglobin data | 38 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 29 |
News Archive
Learning the secrets of how pathogenic bacteria manage to survive in the body of an animal or human may carry great implications for future development of new and better medical treatments. Now, scientists at the University of Maryland School of Dentistry have unraveled one important secret of bacterial adaptation.
Organogenesis, Inc. announced today that it has filed a Premarket Approval Application (PMA) with the U.S. Food and Drug Administration (FDA) for its CelTx(TM), a living cellular construct for oral soft tissue regeneration. If approved, CelTx will be the first, living cell-based technology that is FDA-approved for use in the dental market.
Many cultures hold that stress during pregnancy affects a woman's unborn child. However, there has been surprisingly little research on the topic.
Lumos Pharma, Inc., a clinical stage biopharmaceutical company focused on development and commercialization of therapeutics for rare and neglected diseases, today announced that it has acquired the license for LUM-201, an investigational orally administered small molecule that promotes secretion of growth hormone from the pituitary gland, from Ammonett Pharma LLC.
› Verified 9 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 86 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 639 |
| Percentage of adult patients getting regular hemodialysis at the center | 92 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
Learning the secrets of how pathogenic bacteria manage to survive in the body of an animal or human may carry great implications for future development of new and better medical treatments. Now, scientists at the University of Maryland School of Dentistry have unraveled one important secret of bacterial adaptation.
Organogenesis, Inc. announced today that it has filed a Premarket Approval Application (PMA) with the U.S. Food and Drug Administration (FDA) for its CelTx(TM), a living cellular construct for oral soft tissue regeneration. If approved, CelTx will be the first, living cell-based technology that is FDA-approved for use in the dental market.
Many cultures hold that stress during pregnancy affects a woman's unborn child. However, there has been surprisingly little research on the topic.
Lumos Pharma, Inc., a clinical stage biopharmaceutical company focused on development and commercialization of therapeutics for rare and neglected diseases, today announced that it has acquired the license for LUM-201, an investigational orally administered small molecule that promotes secretion of growth hormone from the pituitary gland, from Ammonett Pharma LLC.
› Verified 9 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Washington Nursing Dialysis with elevated calcium levels.
| Patients with hypercalcemia | 87 |
| Hypercalcemia patient months | 641 |
| Hypercalcemia patients with serumcalcium greater than 10.2 mg | 1 |
| Patients with Serumphosphor | 92 |
| Patients with Serumphosphor less than 3.5 mg/dL | 28 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 31 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 19 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 16 |
| Patients with Serumphosphor greater than 7 mg/dL | 6 |
News Archive
Learning the secrets of how pathogenic bacteria manage to survive in the body of an animal or human may carry great implications for future development of new and better medical treatments. Now, scientists at the University of Maryland School of Dentistry have unraveled one important secret of bacterial adaptation.
Organogenesis, Inc. announced today that it has filed a Premarket Approval Application (PMA) with the U.S. Food and Drug Administration (FDA) for its CelTx(TM), a living cellular construct for oral soft tissue regeneration. If approved, CelTx will be the first, living cell-based technology that is FDA-approved for use in the dental market.
Many cultures hold that stress during pregnancy affects a woman's unborn child. However, there has been surprisingly little research on the topic.
Lumos Pharma, Inc., a clinical stage biopharmaceutical company focused on development and commercialization of therapeutics for rare and neglected diseases, today announced that it has acquired the license for LUM-201, an investigational orally administered small molecule that promotes secretion of growth hormone from the pituitary gland, from Ammonett Pharma LLC.
› Verified 9 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 84 |
| Patient months included in arterial venous fistula and catheter summaries | 501 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 68 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 8 |
News Archive
Learning the secrets of how pathogenic bacteria manage to survive in the body of an animal or human may carry great implications for future development of new and better medical treatments. Now, scientists at the University of Maryland School of Dentistry have unraveled one important secret of bacterial adaptation.
Organogenesis, Inc. announced today that it has filed a Premarket Approval Application (PMA) with the U.S. Food and Drug Administration (FDA) for its CelTx(TM), a living cellular construct for oral soft tissue regeneration. If approved, CelTx will be the first, living cell-based technology that is FDA-approved for use in the dental market.
Many cultures hold that stress during pregnancy affects a woman's unborn child. However, there has been surprisingly little research on the topic.
Lumos Pharma, Inc., a clinical stage biopharmaceutical company focused on development and commercialization of therapeutics for rare and neglected diseases, today announced that it has acquired the license for LUM-201, an investigational orally administered small molecule that promotes secretion of growth hormone from the pituitary gland, from Ammonett Pharma LLC.
› Verified 9 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 68 |
| Hospitalization Rate in facility | 219.3 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 351.7 |
| Hospitalization Rate: Lower Confidence Limit | 141.4 |
News Archive
Learning the secrets of how pathogenic bacteria manage to survive in the body of an animal or human may carry great implications for future development of new and better medical treatments. Now, scientists at the University of Maryland School of Dentistry have unraveled one important secret of bacterial adaptation.
Organogenesis, Inc. announced today that it has filed a Premarket Approval Application (PMA) with the U.S. Food and Drug Administration (FDA) for its CelTx(TM), a living cellular construct for oral soft tissue regeneration. If approved, CelTx will be the first, living cell-based technology that is FDA-approved for use in the dental market.
Many cultures hold that stress during pregnancy affects a woman's unborn child. However, there has been surprisingly little research on the topic.
Lumos Pharma, Inc., a clinical stage biopharmaceutical company focused on development and commercialization of therapeutics for rare and neglected diseases, today announced that it has acquired the license for LUM-201, an investigational orally administered small molecule that promotes secretion of growth hormone from the pituitary gland, from Ammonett Pharma LLC.
› Verified 9 days ago
The rate of readmission show you whether patients who were being treated regularly at Washington Nursing Dialysis were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 22.8 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 31 |
| Readmission Rate: Lower Confidence Limit | 15.9 |
News Archive
Learning the secrets of how pathogenic bacteria manage to survive in the body of an animal or human may carry great implications for future development of new and better medical treatments. Now, scientists at the University of Maryland School of Dentistry have unraveled one important secret of bacterial adaptation.
Organogenesis, Inc. announced today that it has filed a Premarket Approval Application (PMA) with the U.S. Food and Drug Administration (FDA) for its CelTx(TM), a living cellular construct for oral soft tissue regeneration. If approved, CelTx will be the first, living cell-based technology that is FDA-approved for use in the dental market.
Many cultures hold that stress during pregnancy affects a woman's unborn child. However, there has been surprisingly little research on the topic.
Lumos Pharma, Inc., a clinical stage biopharmaceutical company focused on development and commercialization of therapeutics for rare and neglected diseases, today announced that it has acquired the license for LUM-201, an investigational orally administered small molecule that promotes secretion of growth hormone from the pituitary gland, from Ammonett Pharma LLC.
› Verified 9 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at Washington Nursing Dialysis get infections in their blood each year compared to the number of infections expected for the center based on the national average.
| Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
| Infection Rate in facility | 5.56 (Worse than Expected) |
| SIR: Upper Confidence Limit | 8.27 |
| SIR: Lower Confidence Limit | 3.57 |
News Archive
Learning the secrets of how pathogenic bacteria manage to survive in the body of an animal or human may carry great implications for future development of new and better medical treatments. Now, scientists at the University of Maryland School of Dentistry have unraveled one important secret of bacterial adaptation.
Organogenesis, Inc. announced today that it has filed a Premarket Approval Application (PMA) with the U.S. Food and Drug Administration (FDA) for its CelTx(TM), a living cellular construct for oral soft tissue regeneration. If approved, CelTx will be the first, living cell-based technology that is FDA-approved for use in the dental market.
Many cultures hold that stress during pregnancy affects a woman's unborn child. However, there has been surprisingly little research on the topic.
Lumos Pharma, Inc., a clinical stage biopharmaceutical company focused on development and commercialization of therapeutics for rare and neglected diseases, today announced that it has acquired the license for LUM-201, an investigational orally administered small molecule that promotes secretion of growth hormone from the pituitary gland, from Ammonett Pharma LLC.
› Verified 9 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether Washington Nursing Dialysis's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
| Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
| Patients in facility's Transfusion Summary | 53 |
| Transfusion Rate in facility | 81.7 (Worse than Expected) |
| Transfusion Rate: Upper Confidence Limit | 161.2 |
| Transfusion Rate: Lower Confidence Limit | 45 |
News Archive
Learning the secrets of how pathogenic bacteria manage to survive in the body of an animal or human may carry great implications for future development of new and better medical treatments. Now, scientists at the University of Maryland School of Dentistry have unraveled one important secret of bacterial adaptation.
Organogenesis, Inc. announced today that it has filed a Premarket Approval Application (PMA) with the U.S. Food and Drug Administration (FDA) for its CelTx(TM), a living cellular construct for oral soft tissue regeneration. If approved, CelTx will be the first, living cell-based technology that is FDA-approved for use in the dental market.
Many cultures hold that stress during pregnancy affects a woman's unborn child. However, there has been surprisingly little research on the topic.
Lumos Pharma, Inc., a clinical stage biopharmaceutical company focused on development and commercialization of therapeutics for rare and neglected diseases, today announced that it has acquired the license for LUM-201, an investigational orally administered small molecule that promotes secretion of growth hormone from the pituitary gland, from Ammonett Pharma LLC.
› Verified 9 days ago
The rate of mortality show you whether patients who were being treated regularly at Washington Nursing Dialysis lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
| Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
| Patients in facility's Survival Summary | 357 |
| Mortality Rate in facility | 23.8 (Worse than Expected) |
| Mortality Rate: Upper Confidence Limit | 30.9 |
| Mortality Rate: Lower Confidence Limit | 18 |
News Archive
Learning the secrets of how pathogenic bacteria manage to survive in the body of an animal or human may carry great implications for future development of new and better medical treatments. Now, scientists at the University of Maryland School of Dentistry have unraveled one important secret of bacterial adaptation.
Organogenesis, Inc. announced today that it has filed a Premarket Approval Application (PMA) with the U.S. Food and Drug Administration (FDA) for its CelTx(TM), a living cellular construct for oral soft tissue regeneration. If approved, CelTx will be the first, living cell-based technology that is FDA-approved for use in the dental market.
Many cultures hold that stress during pregnancy affects a woman's unborn child. However, there has been surprisingly little research on the topic.
Lumos Pharma, Inc., a clinical stage biopharmaceutical company focused on development and commercialization of therapeutics for rare and neglected diseases, today announced that it has acquired the license for LUM-201, an investigational orally administered small molecule that promotes secretion of growth hormone from the pituitary gland, from Ammonett Pharma LLC.
› Verified 9 days ago
Georgetown University Hospital Location: Renal Dialysis Unit, Washington, District Of Columbia, 20007 Phone: (202) 444-3664 |
Washington Hospital Center Location: Section Of Nephrology, Washington, District Of Columbia, 20010 Phone: (202) 877-5645 |
BMA - Dupont Circle Location: 11 Dupont Cir Nw, Washington, District Of Columbia, 20036 Phone: (202) 483-0176 |
BMA - Columbia Heights Location: 106 Irving St Nw, Washington, District Of Columbia, 20010 Phone: (202) 829-0060 |
Greater Southeast Community Dialysis Center Location: 1350 Southern Ave Se, Washington, District Of Columbia, 20032 Phone: (202) 561-0828 |
News Archive
Learning the secrets of how pathogenic bacteria manage to survive in the body of an animal or human may carry great implications for future development of new and better medical treatments. Now, scientists at the University of Maryland School of Dentistry have unraveled one important secret of bacterial adaptation.
Organogenesis, Inc. announced today that it has filed a Premarket Approval Application (PMA) with the U.S. Food and Drug Administration (FDA) for its CelTx(TM), a living cellular construct for oral soft tissue regeneration. If approved, CelTx will be the first, living cell-based technology that is FDA-approved for use in the dental market.
Many cultures hold that stress during pregnancy affects a woman's unborn child. However, there has been surprisingly little research on the topic.
Lumos Pharma, Inc., a clinical stage biopharmaceutical company focused on development and commercialization of therapeutics for rare and neglected diseases, today announced that it has acquired the license for LUM-201, an investigational orally administered small molecule that promotes secretion of growth hormone from the pituitary gland, from Ammonett Pharma LLC.
› Verified 9 days ago